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Summary
Background: Treatment rates for hepatitis C virus (HCV) have not been compared directly
between HCV mono-infected and HCV—HIV co-infected patients in academic center settings.
Methods: We prospectively enrolled consecutive mono-infected and co-infected subjects at
three academic centers in the USA. Clinical and laboratory data were gathered through inter-
views and medical records. Logistic regression analysis was used to determine the factors
associated with treatment prescription for HCV.
Results: The 241 HCV mono-infected and 158 HCV—HIV co-infected subjects were similar in age,
but there weremore blacks (58.9% vs. 30.7%, p < 0.001) andmales (81.6% vs. 58.5%, p < 0.001) in
the latter group. The co-infected subjects were less likely to have a liver biopsy (43.7% vs. 71.4%,
p < 0.001) or ever receive treatment for HCV (32.3% vs. 62.2%, p < 0.001). In bivariate analysis,
subjects not prescribed treatment for HCV were more likely to be black, have HIV co-infection,
and have ongoing alcohol abuse. In multivariate analysis, black race (odds ratio (OR) 0.44, 95%
confidence interval (CI) 0.28—0.70) and HIV co-infection (OR 0.33, 95% CI 0.21—0.53) were
independently associated with non-prescription of treatment.
* Corresponding author.
E-mail address: butta@dom.pitt.edu (A.A. Butt).
1201-9712/$36.00 # 2008 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
doi:10.1016/j.ijid.2008.06.041
Conclusions: Black race and HIV co-infection are associated with a lower likelihood of treatment
for HCV. Addressing comorbidities in these populations may help to reduce such treatment dis-
parities.
# 2008 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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The last decade has seen significant advances in therapies for
hepatitis C virus (HCV). With currently available pharma-
cotherapy, sustained virologic response rates range from
54% to 56% in HCV mono-infected persons and from 27% to
40% in HCV—HIV co-infected persons.1—5 Despite these suc-
cesses, few data exist on the rates of HCV treatment and
factors associated with non-treatment among HCV mono-
infected and HCV—HIV co-infected individuals. Studies have
been conducted primarily among patients receiving care at
Veterans Affairs (VA) medical centers, where access to HCV
treatment is not dependent on reimbursement issues,6—9 but
this patient population is demographically and socio-econom-
ically different than the general population. Among HCV-
infected patients at VA healthcare facilities, HCV treatment
prescription rates are low in both HCV—HIV co-infected and
HCV mono-infected persons.7,8 For veterans in care at the VA
facilities, non-treatment is associated with certain medical,
psychiatric, and substance abuse comorbidities, conditions
that are more prevalent in this population than in the general
population. To our knowledge, there has been no direct com-
parison of HCV mono-infected and HCV—HIV co-infected per-
sons to determine the differences in treatment rates and
factors associated with non-treatment in a non-VA setting.
To address these issues, we conducted this study to determine
and directly compare the rates of treatment and reasons for
non-treatment for HCV in HCVmono-infected vs. HCV—HIV co-
infected persons in non-VA academic medical center settings.
These results may suggest future interventions to increase
prescription rates of antiviral therapy, which can help to lower
the incidence of HCV-associated liver failure in the HCVmono-
infected and HCV—HIV co-infected populations.
Methods
We performed a cross-sectional study among prospectively
recruited adult HCVmono-infected and HCV—HIV co-infected
patients referred for HCV care to the infectious diseases/HIV
clinics and hepatology clinics of the University of Pittsburgh
Medical Center in Pittsburgh, PA, University of Pennsylvania
Medical Center in Philadelphia, PA, and the University of
Cincinnati Medical Center in Cincinnati, OH. Inclusion criteria
included (1) a positive test for anti-HCV antibody, and (2) at
least one visit for HCV care. Patients were placed in the HCV—
HIV co-infected group if, in addition, they had a positive test
for anti-HIV antibody and/or detectable HIV RNA. Eligible
subjects were identified at all sites through computerized
registries, and all subjects seen between January 2005 and
November 2006 were offered inclusion in this study.
After obtaining informed consent, we interviewed all
subjects using a standard questionnaire to gather information
on demographics, risk factors for HCV and HIV, comorbid
illnesses, substance abuse (tobacco, alcohol, and illicit drugs
as reported by subjects), educational status, history of
incarceration, and number of lifetime sexual partners. Weabstracted additional laboratory and clinical data from sub-
ject medical records at the initial and most recent visits for
HCV care. Liver biopsy data were retrieved from hospital
computerized pathology records, where they were recorded
as modified histology activity index (HAI) score. Necroinflam-
matory (inflammation) and fibrosis scores were retrieved
from the histopathology report and recorded separately.
HCV treatment information was gathered from patient
self-report and confirmed by chart and/or pharmacy records
review. The study was approved by the institutional review
boards of the University of Pittsburgh (ClinicalTrials.gov
identifier NCT00222859), University of Pennsylvania, and
University of Cincinnati.
Our primary outcome measure was prescription of treat-
ment for HCVat any past time, determined from subject self-
report and pharmacy records at each site. Subjects were
considered to have been prescribed HCV treatment if any
prescription for interferon-alpha or pegylated interferon-
alpha (with or without ribavirin) was written for the patient
at any time point, for any duration. Anemia was defined as a
hemoglobin level 13.0 g/dl for men and 12.0 g/dl for
women, neutropenia was defined as a total leukocyte count
<1.5  109 cells/l, and thrombocytopenia was defined as a
platelet count <75  109/l (all at first HCV care visit)
(Table 1).
Baseline subject characteristics were described by using
means and standard deviations for continuous data and
proportions for categorical data. Differences between groups
were assessed by using t-tests or Wilcoxon rank-sum tests, as
appropriate, for continuous data and Chi-square or Fisher’s
exact tests for categorical data. Factors associated with
treatment prescription were tested first in univariate logistic
regression models. Stepwise multivariate logistic regression
was then performed retaining variables that were significant
at p < 0.10 in the univariate model. All analyses were con-
ducted using STATA1 statistical software (Stata Corporation,
College Station, TX, USA). Given our sample sizes for the two
groups and a two-tailed alpha of 0.05, we had 80% power to
detect the following differences in treatment prescription
rates between the HCV—HIV co-infected patients and the
HCV mono-infected patients, respectively: 0.20 vs. 0.33;
0.25 vs. 0.38; 0.30 vs. 0.44, and 0.35 vs. 0.49.
Results
We recruited a total of 399 subjects (241 HCV mono-infected
and 158 HCV—HIV co-infected). The two groups were similar
in age, but there were more blacks (58.9% vs. 30.7%,
p < 0.001) and males (81.6% vs. 58.5%, p < 0.001) in the
HCV—HIV co-infected group (Table 2). HCV—HIV co-infected
subjects also had a lower mean (SD) body mass index com-
pared with the HCV mono-infected subjects (25.8 (5.5) vs.
29.1 (5.6), p < 0.001).
A total of 241 subjects (60.4%) underwent liver biopsy.
HCV—HIV co-infected subjects were less likely to have a liver
biopsy performed than HCVmono-infected subjects (43.7% vs.
Table 1 Summary of definitions used for the study.
Condition Operational definition/extraction method
Medical comorbidities, e.g.,
coronary artery disease, diabetes
Self report and/or chart abstraction
Depression Self report and/or chart abstraction
Ongoing alcohol use Self report and/or chart abstraction
Ongoing injection drug abuse Self report and/or chart abstraction
Diabetes Self report and/or chart abstraction
Anemia Hemoglobin <13.0 g/dl for men; <12.0 g/dl for women
Neutropenia Total leukocyte count <1.5  109 cells/l
Thrombocytopenia Platelet count <75  109/l
HIV infection Positive HIV antibody or HIV RNA PCR
Hepatitis C virus infection Positive HCV antibody
Treatment prescription Self report and/or pharmacy data from medical records
Race, HIV, and treatment for HCV 45171.4%, p < 0.001). The HCV—HIV co-infected patients had
lower mean (SD) fibrosis scores (2.1 (1.3) vs. 2.5 (1.5),
p = 0.04) and inflammation scores (2.6 (1.6) vs. 3.7 (2.0),
p = 0.001) compared to HCVmono-infected subjects (Table 2).
A total of 201 subjects (50.4%) were ever prescribed HCV
therapy. HCV—HIV co-infected subjects were less likely to
have ever initiated treatment for HCV than HCV mono-
infected subjects (32.3% vs. 62.2%, p < 0.001). In addition,
subjects not prescribed treatment were more likely to be of
black race, HIV co-infected, and have ongoing alcohol abuse
(Table 3).
When we examined factors associated with non-receipt of
HCV therapy separately among HCVmono-infected and HCV—Table 2 Baseline characteristics of HCV mono-infected and HCV
HCV mono-infecte
(N = 241)
Mean age (SD), years 49.7 (10.9)
Race
White 65.6
Black 30.7
Hispanic 0.8
Other/unknown 2.9
% Male 58.5
Site
Pittsburgh 51.9
Philadelphia 21.6
Cincinnati 26.6
HCV genotype 1 81.9
Liver biopsy performed 71.4
Body mass index (SD) 29.1 (5.6)
Ever prescribed HCV treatment 62.2
Mean fibrosis scorea,b (SD) 2.5 (1.5)
Mean inflammation scorea,b (SD) 3.7 (2.0)
Nadir CD4 <200/mm3 N/A
Values are % unless stated otherwise.
HCV, hepatitis C virus; N/A, not applicable; NS, not significant.
a Modified HAI (histologic activity index) score.
b Fibrosis scores were available for 159 HCV mono-infected subjects an
were available for 69 HCV mono-infected and 58 HCV—HIV co-infectedHIV co-infected subjects, fewer subjects of black race were
prescribed treatment in each group (though the difference
did not reach statistical significance in the HCV—HIV co-
infected group) (Table 4). In univariate analysis, black race
(odds ratio (OR) 0.39, 95% confidence interval (CI) 0.26—
0.59), HIV co-infection (OR 0.29, 95% CI 0.19—0.44), and
ongoing alcohol abuse (OR 0.52, 95% CI 0.30—0.89) were
associated with a lesser likelihood of receiving treatment
for HCV (Table 5). In multivariate analysis, black race
(adjusted OR 0.44, 95% CI 0.28—0.70) and HIV co-infection
(adjusted OR 0.33, 95% CI 0.21—0.53) were associated with a
lower likelihood of treatment prescription, while anemia was
associated with an increased likelihood of treatment pre-—HIV co-infected subjects.
d HCV—HIV co-infected
(N = 158)
p-Value
48.4 (7.4) NS
<0.001
36.1
58.9
2.5
2.5
81.6 <0.001
0.01
42.4
34.8
22.8
82.9 NS
43.7 <0.001
25.8 (5.5) <0.001
32.3 <0.001
2.1 (1.3) 0.04
2.6 (1.6) 0.001
32.9 N/A
d 65 HCV—HIV co-infected subjects, and necroinflammatory scores
subjects.
Table 3 Characteristics of subjects prescribed treatment for HCV vs. those who were not prescribed treatment for HCV.
Prescribed treatment
(N = 201)
Not prescribed treatment
(N = 198)
p-Value
Mean age (SD), years 48.6 (10.0) 49.8 (9.7) NS
Race <0.001
White 65.2 42.4
Black 31.3 52.5
Hispanic 2.0 1.0
Other/unknown 1.5 4.1
% Male 67.2 68.2 NS
Site NS
Pittsburgh 51.2 45.0
Philadelphia 23.9 29.8
Cincinnati 24.9 25.2
HCV genotype 1 82.4 82.1 NS
Liver biopsy performed 84.1 36.4 <0.001
Mean body mass index (SD) 27.8 (5.9) 27.6 (5.7) NS
Evidence of liver injury
(either elevated ALT or
liver fibrosis stage 2)
87.0 87.9 NS
HIV 25.4 54.0 <0.001
Coronary artery disease 4.5 5.0 NS
Diabetes 11.9 13.6 NS
Depression 49.2 50.5 NS
Ongoing alcohol abuse 12.0 20.9 0.02
Injection drug abuse 52.7 58.1 NS
Anemia 26.9 19.7 NS
Neutropenia 1.0 0.5 NS
Thrombocytopenia 4.3 4.1 NS
Any contraindication present 70.2 70.7 NS
Values are % unless stated otherwise.
HCV, hepatitis C virus; NS, not significant; ALT, serum alanine aminotransferase.
452 A.A. Butt et al.scription (adjusted OR 2.16, 95% CI 1.26—3.70) (Table 6).
When we analyzed the HCV mono-infected and HCV—HIV co-
infected groups separately, black race was associated with a
lower likelihood of receiving treatment in each group, with a
lower odds ratio in the latter group compared with the
former.
Subjects who were HCV—HIV co-infected were more likely
to have at least one comorbidity compared with HCV mono-
infected subjects (80.4% vs. 63.9%, p < 0.001; results not
shown). The following comorbidities/contraindications were
more likely to be present in blacks ( p < 0.05): diabetes,
autoimmune disease, intravenous drug use, and anemia prior
to treatment. Blacks were also more likely to have at least
one comorbidity compared to non-blacks, but this did not
reach statistical significance (74.2% vs. 67.7%, p = 0.16).
Discussion
Our study demonstrates that there are significant differences
in rates of treatment prescription for HCV between HCV
mono-infected and HCV—HIV co-infected persons. HIV co-
infection is an independent predictor of not receiving treat-
ment for HCV. This effect persists even after adjusting for
age, minority race, and other comorbidities. Such an effect
has been demonstrated previously in veterans in care withHCV infection,8 but has not been shown in patients presenting
to university medical centers. While HIV infection is not a
contraindication for treatment for HCV, there are several
possible reasons for this disparity. The response to currently
available pharmacotherapy for HCV is lower in the HCV—HIV
co-infected persons than in HCV mono-infected persons.4,5,10
Persons with HCV—HIV co-infection are more likely to have
medical, psychiatric, and substance abuse comorbidities that
could reduce HCV treatment eligibility.8,11,12 In addition, the
majority of HCV—HIV co-infected patients receive complex
antiretroviral drug regimens with potential drug interactions
with ribavirin.13 Due to such factors, healthcare providers
may be reluctant to initiate treatment for HCV in HCV—HIV
co-infected persons. Whether other provider factors, e.g.,
provider level of comfort in prescribing anti-HCV therapy,
knowledge, attitudes, and beliefs regarding HCV infection
play any part in treatment decisions for HCV is unknown.
We also found that blacks are less likely to receive treat-
ment for HCV than whites. Racial disparities have been
observed for other treatment modalities.14—16 Among the
HCV-infected, patients of black race are less likely to achieve
a sustained virologic response compared with white
patients.17,18 The reason for these differences is not known,
but these data might affect provider decisions regarding
treatment prescription for HCV in blacks. Additionally,
Table 5 Factors associated with treatment prescription for HCV (univariate logistic regression).
Overall OR (95% CI) HCV mono-infected
OR (95% CI)
HCV—HIV co-infected
OR (95% CI)
Age (per year increase) 1.01 (0.99—1.03) 1.00 (0.98—1.03) 1.04 (0.99—1.09)
Race
White 1.00 1.00 1.00
Black 0.39 (0.26—0.59) 0.45 (0.26—0.79) 0.62 (0.31—1.24)
Hispanic 1.28 (0.23—7.16) Too few observations 1.59 (0.21—12.13)
Other/unknown 0.24 (0.06—0.93) 0.18 (0.04—0.96) 0.53 (0.05—5.42)
Female sex 1.05 (0.69—1.59) 0.73 (0.43—1.25) 0.76 (0.31—1.86)
HCV genotype 1 1.02 (0.58—1.81) 1.25 (0.61—2.57) 0.75 (0.28—1.99)
Body mass index 1.01 (0.97—1.04) 0.98 (0.93—1.02) 0.97 (0.90—1.03)
Evidence of liver injurya 0.92 (0.37—2.31) 0.46 (0.10—2.12) 1.68 (0.41—6.98)
HIV 0.29 (0.19—0.44) - -
Coronary artery disease 0.88 (0.35—2.22) 0.49 (0.14—1.65) 2.19 (0.52—9.14)
Diabetes 0.86 (0.48—1.55) 0.67 (0.33—1.36) 0.83 (0.25—2.77)
Depression 0.95 (0.64—1.41) 1.08 (0.63—1.83) 1.78 (0.86—3.67)
Ongoing alcohol abuse 0.52 (0.30—0.89) 0.56 (0.25—1.23) 0.72 (0.32—1.64)
Injection drug abuse 0.80 (0.54—1.20) 1.02 (0.61—1.72) 0.82 (0.41—1.63)
Anemia 1.50 (0.94—2.39) 1.43 (0.73—2.81) 2.42 (1.18—4.97)
HCV, hepatitis C virus; OR, odds ratio; CI, confidence interval.
a Either elevated serum alanine aminotransferase or liver fibrosis stage 2.
Table 4 A comparison of subjects prescribed treatment for HCV with those who were not prescribed treatment by HIV status.
HCV mono-infected HCV—HIV co-infected
Prescribed
treatment
(N = 150)
Not prescribed
treatment
(N = 91)
p-Value Prescribed
treatment
(N = 51)
Not prescribed
treatment
(N = 107)
p-Value
Mean age (SD) 49.8 (9.9) 49.5 (12.3) NS 49.7 (7.4) 47.7 (7.4) NS
Race 0.006 NS
White 72.7 53.8 43.1 32.7
Black 24.7 40.7 51.0 62.6
Hispanic 1.3 0.0 3.9 1.9
Other/unknown 1.3 5.5 2.0 2.8
% Male 53.8 61.3 NS 84.3 80.4 NS
HCV genotype 1 83.1 79.7 NS 80.4 84.5 NS
Liver biopsy performed 88.0 44.0 <0.001 72.6 29.9 <0.001
Mean body mass index (SD) 28.8 (5.5) 29.6 (5.8) NS 25.1 (6.1) 26.1 (5.2) NS
Evidence of liver injury
(either elevated ALT or
liver fibrosis stage 2)
86.6 93.3 NS 88.6 82.1 NS
Coronary artery disease 3.3 6.6 NS 7.8 3.7 NS
Diabetes 13.3 18.7 NS 7.8 9.4 NS
Depression 41.3 40.0 NS 72.6 59.8 NS
Ongoing alcohol abuse 9.4 15.7 NS 19.6 25.2 NS
Injection drug abuse 50.0 49.5 NS 60.8 65.4 NS
Anemia 22.0 16.5 NS 41.2 22.4 0.02
Neutropenia 1.3 0.0 NS 0.0 0.9 NS
Thrombocytopenia 5.7 5.6 NS 0.0 3.0 NS
Any contraindication present 64.7 62.6 NS 86.3 77.6 NS
Values are % unless stated otherwise.
HCV, hepatitis C virus; NS, not significant; ALT, serum alanine aminotransferase.
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Table 6 Factors associated with treatment prescription for HCV (multivariate logistic regression)a.
Overall OR (95% CI) HCV mono-infected
OR (95% CI)
HCV—HIV co-infected
OR (95% CI)
Black race 0.44 (0.28—0.70) 0.44 (0.25—0.78) 0.28 (0.12—0.68)
HIV 0.33 (0.21—0.53) - -
Ongoing alcohol abuse 0.58 (0.31—1.06) NS NS
Anemia 2.16 (1.26—3.70) NS 3.49 (1.47—8.28)
HCV, hepatitis C virus; OR, odds ratio; CI, confidence interval.
a Stepwise forward multivariable regression analysis, retaining variables with p < 0.1.
454 A.A. Butt et al.prevalence of certain medical and psychiatric comorbidities
and substance abuse rates are higher in blacks,19 and these
represent additional barriers to prescription of HCV treat-
ment.
Only a small number of HCV-infected persons in our study
ever underwent a liver biopsy, despite being evaluated at
tertiary care referral centers. HCV—HIV co-infected persons
were less likely to undergo liver biopsy compared with HCV
mono-infected persons. This might be due to provider reluc-
tance to perform an invasive procedure in HCV—HIV co-
infected patients who are more likely to have concomitant
comorbidities and a reduced likelihood of achieving a sus-
tained virologic response. The very low rate of obtaining a
liver biopsy in the HCV—HIV co-infected patients (36.4%)
suggests that non-invasive tests to assess hepatic fibrosis,
either by use of serum markers (e.g., AST-to-platelet ratio
index, FIB-4, SHASTA, or FibroSURE) or imaging modalities
(e.g., elastometry) may be of value in this population.20
These tests, currently still under investigation, represent an
alternative to the liver biopsy. Examination of the liver
biopsy results in our study demonstrated lower mean
necroinflammatory and fibrosis scores among HCV—HIV co-
infected subjects compared with HCV mono-infected sub-
jects. Since liver damage due to HCV is immunologically
mediated, one plausible explanation is that the co-infected
subjects had lesser damage due to a relatively suppressed
immune system.
Our study has some limitations. It may not be represen-
tative of the HCV-infected population in general due to a
likely referral bias. It is plausible that the patients referred to
tertiary care centers are believed to be better candidates for
HCV therapy by their primary care providers, implying that
the treatment prescription rates in the general population
may be even lower than what we found in our study. The
laboratory data were not collected at predetermined study
points, and were retrieved from the results routinely per-
formed for clinical care of the patients. Furthermore, the
liver biopsy results were read by different pathologists. The
strengths of our study include prospective and uniform data
collection. To our knowledge, ours is the first study to directly
compare HCV treatment rates in the HCV mono-infected and
HCV—HIV co-infected subjects receiving care at academic
medical centers.
In conclusion, we found substantial disparities in the
treatment of HCV. Blacks and HCV—HIV co-infected persons
are less likely to receive treatment for HCV than whites or
HCV mono-infected persons. Part of this disparity may be
explained by the differences in comorbidities in blacks and
those with HIV co-infection. Addressing comorbidities may
help reduce this disparity in treatment.Acknowledgments
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